LACDR

Universiteit Leiden

List
Filter

Found 37 results. Export: Tagged | XML

Filters: keyword is Adenosine [Clear All Filters]

2005

Schaddelee, M.P., Collins, S.D., DeJongh, J., de Boer, A.G., Ijzerman, A.P., Danhof, M. , Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain, Eur J Pharmacol, vol. 514, no. 2-3, pp. 131-40.

Schaddelee, M.P., Read, K.D., Cleypool, C.G., Ijzerman, A.P., Danhof, M., de Boer, A.G. , Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents, Eur J Pharm Sci, vol. 24, no. 1, pp. 59-66.

2004

Schaddelee, M.P., Dejongh, J., Collins, S.D., de Boer, A.G., Ijzerman, A.P., Danhof, M. , Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5'deoxy-N6-cylopentyladenosine in the mononeuropathic rat, Eur J Pharmacol, vol. 504, no. 1-2, pp. 7-15.

Schaddelee, M.P., Groenendaal, D., DeJongh, J., Cleypool, C.G., AP, I.J., De Boer, A.G., Danhof, M. , Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists, J Pharmacol Exp Ther, vol. 311, no. 3, pp. 1138-46.

2003

Bueters, T.J., AP, I.J., van Helden, H.P., Danhof, M. , Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats, Toxicol Appl Pharmacol, vol. 192, no. 1, pp. 86-94.

Bueters, T.J., van Duivenvoorde, L.M., Danhof, M., AP, I.J., van Helden, H.P. , Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree, Eur J Pharmacol, vol. 481, no. 2-3, pp. 141-6.

Schaddelee, M.P., Voorwinden, H.L., Groenendaal, D., Hersey, A., Ijzerman, A.P., Danhof, M., De Boer, A.G. , Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships, Eur J Pharm Sci, vol. 20, no. 3, pp. 347-56.

Bueters, T.J., van Helden, H.P., AP, I.J., Danhof, M. , Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action, Neurosci Lett, vol. 343, no. 1, pp. 57-61.

Schaddelee, M.P., Voorwinden, H.L., van Tilburg, E.W., Pateman, T.J., Ijzerman, A.P., Danhof, M., de Boer, A.G. , Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives, Eur J Pharm Sci, vol. 19, no. 1, pp. 13-22.

Bueters, T.J., Joosen, M.J., van Helden, H.P., Ijzerman, A.P., Danhof, M. , Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin, J Pharmacol Exp Ther, vol. 304, no. 3, pp. 1307-13.

2002

Bueters, T.J., Groen, B., Danhof, M., AP, I.J., Van Helden, H.P. , Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication, Arch Toxicol, vol. 76, no. 11, pp. 650-6.

1999

Van der Graaf, P.H., Van Schaick, E.A., Visser, S.A., De Greef, H.J., Ijzerman, A.P., Danhof, M. , Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo, J Pharmacol Exp Ther, vol. 290, no. 2, pp. 702-9.

1998

van Schaick, E.A., Zuideveld, K.P., Tukker, H.E., Langemeijer, M.W., Ijzerman, A.P., Danhof, M. , Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action, J Pharmacol Exp Ther, vol. 287, no. 1, pp. 21-30.

van Schaick, E.A., Tukker, H.E., Roelen, H.C., AP, I.J., Danhof, M. , Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats, Br J Pharmacol, vol. 124, no. 3, pp. 607-18.

Snoeck, E., Ver Donck, K., Jacqmin, P., Van Belle, H., Dupont, A.G., Van Peer, A., Danhof, M. , Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine, J Pharmacol Exp Ther, vol. 286, no. 1, pp. 142-9.

1997

Van der Graaf, P.H., Danhof, M. , Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling, Int J Clin Pharmacol Ther, vol. 35, no. 10, pp. 442-6.

van Schaick, E.A., de Greef, H.J., Langemeijer, M.W., Sheehan, M.J., AP, I.J., Danhof, M. , Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats, Br J Pharmacol, vol. 122, no. 3, pp. 525-33.

Van Schaick, E.A., Math-ot, R.A., Gubbens-Stibbe, J.M., Langemeijer, M.W., Roelen, H.C., Ijzerman, A.P., Danhof, M. , 8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo, J Pharmacol Exp Ther, vol. 283, no. 2, pp. 800-8.

Van Der Graaf, P.H., Van Schaick, E.A., Math-ot, R.A., Ijzerman, A.P., Danhof, M. , Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors, J Pharmacol Exp Ther, vol. 283, no. 2, pp. 809-16.

Snoeck, E., Piotrovskij, V., Jacqmin, P., Van Peer, A., Danhof, M., Ver Donck, K., Woestenborghs, R., Van Belle, H., Van Bortel, L., Van Gool, R., Dupont, A.G., Heykants, J. , Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates, Br J Clin Pharmacol, vol. 43, no. 6, pp. 603-12.

van Schaick, E.A., de Greef, H.J., Ijzerman, A.P., Danhof, M. , Physiological indirect effect modeling of the antilipolytic effects of adenosine A1-receptor agonists, J Pharmacokinet Biopharm, vol. 25, no. 6, pp. 673-94.

van Schaick, E.A., Kulkarni, C., von Frijtag Drabbe Kunzel, J.K., Mathot, R.A., Cristalli, G., AP, I.J., Danhof, M. , Time course of action of three adenosine A1 receptor agonists with differing lipophilicity in rats: comparison of pharmacokinetic, haemodynamic and EEG effects, Naunyn Schmiedebergs Arch Pharmacol, vol. 356, no. 6, pp. 827-37.

1996

Snoeck, E., Jacqmin, P., Van Peer, A., Danhof, M., Ver Donck, K., Van Belle, H., Woestenborghs, R., Crabbe, R., Van Gool, R., Dupont, A., Heykants, J. , The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine, Br J Clin Pharmacol, vol. 42, no. 5, pp. 605-13.

Mathoot, R.A., Soudijn, W., Breimer, D.D., Ijzerman, A.P., Danhof, M. , Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo, Br J Pharmacol, vol. 118, no. 2, pp. 369-77.

Van Schaick, E.A., Jacobson, K.A., Kim, H.O., AP, I.J., Danhof, M. , Hemodynamic effects and histamine release elicited by the selective adenosine A3 receptor agonist 2-Cl-IB-MECA in conscious rats, Eur J Pharmacol, vol. 308, no. 3, pp. 311-4.

LACDR